516 results on '"Själander, Anders"'
Search Results
2. Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants
3. Entrustable professional activities (EPAs) for undergraduate medical education – development and exploration of social validity
4. Direct oral anticoagulants: patient reported adherence and minor bleedings
5. The impact of Covid-19 in patients with chronic myeloid leukemia—a nationwide population-based study
6. #430 Risk factors for major bleeding in patients with non-valvular atrial fibrillation and CKD G3-G5D on oral anticoagulants
7. Celiac disease and upper secondary school achievement in Sweden A retrospective cohort study
8. Risk factors for major bleeding in patients with atrial fibrillation and CKD G3–G5D on oral anticoagulants.
9. ABO Blood Groups, RhD Factor and Their Association with Subclinical Atherosclerosis Assessed by Carotid Ultrasonography
10. Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera—A matched nationwide population‐based study
11. Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
12. Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera : a matched nationwide population-based study
13. ABO blood groups, RhD factor and their association with subclinical atherosclerosis assessed by carotid ultrasonography
14. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
15. Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants
16. Warfarin treatment quality and outcomes in patients with non-valvular atrial fibrillation and CKD G3-G5D
17. Predictors for INR-control in a well-managed warfarin treatment setting
18. Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event—A population based cohort study
19. Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event : a population based cohort study
20. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
21. Warfarin treatment quality and outcomes in patients with non-valvular atrial fibrillation and CKD G3-G5D
22. Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants
23. Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D
24. Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
25. Additional file 1 of Celiac disease and upper secondary school achievement in Sweden A retrospective cohort study
26. Venous thromboembolism and cancer risk
27. Bleeding complications in venous thrombosis patients on well-managed warfarin
28. Incidence and risk factors of venous thromboembolism in men and women
29. MO758: Warfarin Treatment Quality and Outcomes in Patients with Non-Valvular Atrial Fibrillation and Chronic Kidney Disease Including Patients on Dialysis
30. Incidence and risk factors of venous thromboembolism in men and women
31. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors : Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
32. Fem år med kunskapsprovet har gett oss 503 kompetenta kollegor
33. Time to initiation of lipid-lowering drugs for subclinical atherosclerosis : sub-study of VIPVIZA randomized controlled trial, with single-arm cross-over
34. Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D
35. Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis
36. Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register
37. Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
38. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study
39. Time to initiation of lipid-lowering drugs for subclinical atherosclerosis: sub-study of VIPVIZA randomized controlled trial, with single-arm cross-over
40. Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population
41. Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis
42. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
43. Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome—A retrospective observational study
44. Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population.
45. Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome : A retrospective observational study
46. Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
47. Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
48. Disease Relapse After Tyrosine Kinase Inhibitor Treatment Discontinuation in Chronic Myeloid Leukaemia is Related to Both Low Number and Impaired Function of NK Cells: WS5.10
49. Atrial fibrillation patients do not benefit from acetylsalicylic acid
50. Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.